Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Schrodinger, Inc. (symbol: SDGR) is a top-tier provider of state-of-the-art molecular simulations and enterprise software solutions, catering primarily to the pharmaceutical, biotechnology, and materials science industries. With its pioneering software, Schrodinger empowers scientists to accelerate research and development, cut down on research expenses, and make groundbreaking discoveries that might not be feasible otherwise.
Established in 1990, Schrodinger has continually invested in fundamental research, leading to numerous scientific breakthroughs in drug discovery and materials science. The company's researchers have contributed hundreds of peer-reviewed scientific publications, often cited as significant works in their respective fields.
Schrodinger operates through two main segments: Software and Drug Discovery. The Software segment focuses on selling advanced software that revolutionizes drug discovery across the life sciences industry. It also caters to customers in materials science. The Drug Discovery segment generates revenue from a portfolio of preclinical and clinical programs, both internally developed and through collaborations.
Schrodinger has established profound partnerships and collaborations with companies in biotechnology, pharmaceuticals, chemicals, and electronics. One notable collaboration is with Nimbus Therapeutics, a biotech firm co-founded by Schrodinger. The company's global presence includes operations in the U.S., Europe, Japan, and India.
Recent achievements highlight Schrodinger's continuous innovation and success. The predictive power of its software solutions has led to significant advancements in scientific research, enhancing the efficiency and efficacy of drug discovery processes. Schrodinger's commitment to excellence and scientific integrity ensures it remains at the forefront of its industry, driving forward the boundaries of what is possible in molecular simulations and drug discovery.
Structure Therapeutics Inc. (NASDAQ: GPCR), backed by Qiming Venture Partners, successfully debuted on Nasdaq on February 3, 2023. Issued at $15.00 per ADS, it opened at $25.00, marking a 66.67% increase and a market cap of $915 million. Qiming Venture Partners has been an early investor since 2019. Structure Therapeutics focuses on converting biologics into orally available small molecules, targeting G-protein-coupled receptors. Their pipeline includes GSBR-1290 for type-2 diabetes and ANPA-0073 for pulmonary conditions, with significant studies completed in September 2022.
Schrödinger (Nasdaq: SDGR) will participate in the SVB Securities Global Biopharma Conference on February 14, 2023, at 1:00 p.m. ET. The presentation details will be available under the "News & Events" section on their website and archived for seven days. Schrödinger is known for its innovative physics-based computational platform that accelerates the discovery of novel molecules for drug and material development. Founded in 1990, the company has over 800 employees and partners globally in over 70 countries.
Schrödinger, Inc. (Nasdaq: SDGR) recently announced the granting of non-statutory stock options for 14,300 shares and restricted stock units (RSUs) for 4,350 shares to new employees as part of their 2021 Inducement Equity Incentive Plan. The stock options, priced at $23.83 per share, will vest over four years with specific conditions based on the employees' service duration. RSUs will also vest over four years. This move aims to attract talent and enhance the company's growth in therapeutic and materials discovery, leveraging its advanced computational platform.
Schrödinger (Nasdaq: SDGR) announced significant developments, including an expanded collaboration with Bristol Myers Squibb to target neurology and a new partnership with Otsuka Pharmaceutical for CNS diseases. The company reported progress on its LRRK2 inhibitor program aimed at Parkinson's disease and emphasized its 2022 achievements, such as FDA clearance for SGR-1505 and multiple new drug discovery collaborations. For 2023, Schrödinger aims to advance its clinical trials and expand its collaborative drug discovery efforts, with financial results scheduled for February 28, 2023.
Schrödinger, Inc. (Nasdaq: SDGR) announced the grant of non-statutory stock options for 26,350 shares to seven newly hired employees on
Schrödinger, Inc. (Nasdaq: SDGR) presented promising preclinical data on its CDC7 inhibitor, SGR-2921, at the American Society of Hematology meeting. The data demonstrate strong anti-tumor activity in multiple acute myeloid leukemia (AML) models, both as a monotherapy and in combination with standard care agents. Plans are in place to submit an Investigational New Drug (IND) application to the FDA in the first half of 2023, followed by a Phase 1 clinical trial for patients with relapsed/refractory AML.
On November 15, 2022, Schrödinger granted 32,165 non-statutory stock options to eight newly hired employees as part of its 2021 Inducement Equity Incentive Plan. The options have an exercise price of $22.27 per share, matching the stock's closing price on the grant date. Vesting for U.S. employees occurs in monthly installments over four years, while international employees will vest annually over three years. Schrödinger utilizes a physics-based computational platform to enhance drug discovery and materials development, with a workforce of around 800 across 70 countries.
Schrödinger (Nasdaq: SDGR) announced participation in a fireside chat at the Jefferies 13th Annual London Healthcare Conference on November 16, 2022, at 3:50 p.m. GMT (10:50 a.m. ET). The event aims to showcase Schrödinger's innovative physics-based computational platform that significantly enhances drug and material discovery. Interested parties can access the live discussion on the company's website, where it will also be archived for about seven days. Schrödinger operates globally with around 800 employees, focusing on unmet medical needs through its collaborative and proprietary programs.
Schrödinger, Inc. (SDGR) reported a 24% increase in total revenue for Q3 2022, reaching $37 million, driven by a 121% surge in drug discovery revenue. The company's software revenue remained stable at $24.7 million. However, operating expenses rose 38% to $63.4 million, resulting in a net loss of $39.9 million. Schrödinger has narrowed its full-year revenue guidance to $167 million to $175 million. Exciting developments include the opening of a Phase 1 trial for MALT1 inhibitor SGR-1505 and upcoming data presentations for CDC7 inhibitor SGR-2921 at the ASH meeting.
Schrödinger, Inc. (Nasdaq: SDGR) has announced the presentation of new preclinical data on its CDC7 inhibitor, SGR-2921, at the American Society of Hematology's 64th Annual Meeting in New Orleans from December 10-13, 2022. CDC7 is a cell cycle kinase crucial for DNA replication, and its inhibition serves as a promising approach for treating cancers like acute myeloid leukemia (AML). The company plans to initiate a Phase 1 trial of SGR-2921 for relapsed/refractory AML in the second half of 2023.
FAQ
What is the current stock price of Schrodinger (SDGR)?
What is the market cap of Schrodinger (SDGR)?
What does Schrodinger, Inc. do?
When was Schrodinger, Inc. founded?
What are the main segments of Schrodinger’s business?
How does Schrodinger generate revenue?
What industries does Schrodinger’s software cater to?
What are some of Schrodinger’s recent achievements?
Where are Schrodinger’s operations located?
What is Nimbus Therapeutics?
How has Schrodinger contributed to scientific research?
What makes Schrodinger's software unique?
